StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst
October 28, 2021 8:41 AM
Earlier today, alongside its Q3 report, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the planned CEO transition of John Maraganore, Ph.D ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Corporate News
FDA
Management Changes
Momentum Movers
Trader Talk
Next Articles
Alnylam Pharma (ALNY) Misses Q3 EPS by 15c
October 28, 2021 8:13 AM
Alnylam Pharma (ALNY) Announces Planned Retirement of CEO John Maraganore
October 28, 2021 7:56 AM
Alnylam Pharma (ALNY) Announces Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran
October 27, 2021 4:00 PM